About Us
OrthoFix Inc. has pioneered advanced orthopedic solutions by developing a nanocomposite PMMA-based bone cement that has transformed orthopedic fixation. We have combined bioglass and graphene oxide (GO) into a proprietary formulation that has significantly improved mechanical strength, cytocompatibility, and implant longevity. Through continuous refinement driven by rigorous research and clinical insight, we have enhanced patient outcomes, minimized surgical complications, and addressed critical limitations of traditional bone cement. Operating with a global vision, we have positioned ourselves as a trusted partner to healthcare providers and surgical specialists worldwide.
Vision
To stand as a globally admired and trusted leader in medical technologies, shaping the future of orthopedic healthcare.
Mission
To improve lives with innovative PMMA-based bone cement solutions, optimizing patient care and surgical outcomes.
Advantages
Extended implant lifespan
Nanocomposite PMMA-based bone cement
Proprietary blend of bioglass and graphene oxide
Reduced risk of implant failure
Higher elastic modulus and bond strength
Superior cytocompatibility and osteoinductivity
Problems To Solve
Osteoporosis-Related
Fractures
Osteoporosis remains a leading cause of bone fragility worldwide, significantly heightening the risk of fractures in the aging population. The progressive loss of bone density creates long-term complications, elevating healthcare burdens and reducing quality of life.
Joint Replacement Complications
Millions of joint replacements are performed each year, but complications such as aseptic loosening, infection, and instability remain prevalent. These issues often lead to revision surgeries, highlighting the urgent need for stronger, more reliable fixation materials.
Bone Cement Leakage in
Vertebroplasty
Vertebroplasty procedures across the world frequently encounter PMMA bone cement leakage, with incidences reported at concerning levels. This leakage compromises treatment outcomes and patient safety, underscoring the need for improved formulations.
Our Innovative Solutions
Fracture Support
We have engineered our nanocomposite PMMA bone cement to provide stable, reliable support during orthopedic procedures. This formulation directly addresses the increased fragility and fracture risks faced by aging and osteoporotic patients. By enhancing cement stability and bonding strength, our solution helps reduce complications and accelerates recovery timelines.
Joint Replacement Longevity
Our advanced bone cement technology elevates bond strength and mechanical resilience to combat common complications such as aseptic loosening and implant failure. This has enabled surgeons to improve the long-term success of joint replacements, offering patients durable, lasting outcomes and reducing the need for costly revision surgeries.
Leakage Prevention
Recognizing the challenges posed by PMMA bone cement leakage during vertebroplasty, we have developed a proprietary bioglass-graphene oxide composite to minimize this risk. This innovation ensures safer, more effective cement application, protecting surrounding tissues and enhancing procedure success rates.
Target Market
Hospitals
Private Orthopedic Centres
Ambulatory Surgical Centres
Our Founder
Ke Sun
Chief Executive Officer
Mr. Ke Sun is the founder and chief executive behind OrthoFix Inc.’s next-generation bone-cement platform, uniting deep chemical-engineering expertise with end-to-end business leadership. Holding Bachelor’s and Master’s degrees in Chemical Engineering from Sichuan University, he spent nearly a decade leading large, safety-critical programs as Director of Process & Piping at Sinopec Ningbo Engineering, before stepping into enterprise-scale commercialization as Vice President of Global Business at Maxiglas Corp. Today he channels that technical rigor and operating discipline into OrthoFix—setting product direction, regulatory readiness, and go-to-market execution.
Sun’s edge is a rare combination: he has managed complex engineering organizations, negotiated international commercial objectives, and now orchestrated a tightly aligned product, operations, and finance plan at OrthoFix—including a staged hiring model, disciplined spend on product development, and a revenue strategy diversified across direct, distribution, and licensing streams. Stakeholders value his ability to turn clinical feedback into material-level improvements, keep regulatory workstreams on track, and build partnerships that compound market reach—making him the right leader to scale OrthoFix from breakthrough formulation to standard of care
